5.6 USD
-0.17 (-2.95%)
5.64 USD
+0.04 (+0.71%)
Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
In the past year ORGO has reported a negative cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
ORGO has a Return On Assets of -2.63%. This is amongst the best in the industry. ORGO outperforms 87.33% of its industry peers.
ORGO's Return On Equity of -3.47% is amongst the best of the industry. ORGO outperforms 89.22% of its industry peers.
ORGO has a better Return On Invested Capital (0.16%) than 88.66% of its industry peers.
ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO's Operating Margin of 0.18% is amongst the best of the industry. ORGO outperforms 88.85% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 74.49%, ORGO belongs to the top of the industry, outperforming 83.18% of the companies in the same industry.
ORGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
ORGO has an Altman-Z score of 4.83. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
ORGO has a better Altman-Z score (4.83) than 72.59% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ORGO outperforms 45.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.83 |
ROIC/WACC0.02
WACC8.91%
2.3 Liquidity
ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a worse Current ratio (3.32) than 61.06% of its industry peers.
ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ORGO is outperformed by 64.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
The Revenue has been growing slightly by 2.24% in the past year.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.27% yearly.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 8.70% on average per year.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 560.00 indicates a quite expensive valuation of ORGO.
Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 88.66% of the companies listed in the same industry.
ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.38.
Based on the Price/Forward Earnings ratio of 37.86, the valuation of ORGO can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 91.49% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.83. ORGO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 560 | ||
| Fwd PE | 37.86 |
4.2 Price Multiples
91.49% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.29 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 29.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.6
-0.17 (-2.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.82%
Inst Owner Change-1.32%
Ins Owners31.5%
Ins Owner Change-0.26%
Market Cap710.70M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (54.82%)
Short Float %16.05%
Short Ratio6.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)6.25%
PT rev (3m)6.25%
EPS NQ rev (1m)35.48%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)216.67%
EPS NY rev (3m)450%
Revenue NQ rev (1m)3.66%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)5.49%
Revenue NY rev (3m)5.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 560 | ||
| Fwd PE | 37.86 | ||
| P/S | 1.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | 2.05 | ||
| EV/EBITDA | 35.29 |
EPS(TTM)0.01
EY0.18%
EPS(NY)0.15
Fwd EY2.64%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 4.83 |
F-Score2
WACC8.91%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
What is the valuation status for ORGO stock?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
How profitable is ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the valuation of ORGANOGENESIS HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 560 and the Price/Book (PB) ratio is 1.84.
Can you provide the expected EPS growth for ORGO stock?
The Earnings per Share (EPS) of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to decline by -58% in the next year.